Abstract:Introduction: Budesonide/formoterol (Symbicort®) Maintenance And Reliever Therapy (SMART) is an effective and well tolerated treatment option for patients with asthma. We compared the cost effectiveness from a societal perspective of this one-inhaler regimen with that of maintenance salmeterol/fluticasone propionate (Seretide®) plus salbutamol (albuterol) as needed (Seretide® Fixed Combination [SFC]).Study design: A cost-effectiveness analysis was performed based on effectiveness and resource-utilisation data collected prospectively in a randomised, 12-month study performed in 2143 patients in 16 countries. Resource utilisation data were pooled and unit costs (€, year 2003 values) from Italy, France, the UK and Germany were used to generate estimates of direct and total costs per patient per year and cost per severe exacerbation avoided.Methods: Adolescents and adults with asthma (n = 2143; mean forced expiratory volume in 1 second [FEV1] 73% predicted; mean inhaled corticosteroid [ICS] dose 884 µg/day) were randomised to SMART or SFC. The effectiveness measure used was the number of severe exacerbations per patient per year. Direct costs included medication use (budesonide/formoterol 160µg/4.5µg or salmeterol/fluticasone 50µg/100µg, 50µg/250µg or 50µg/500µg plus salbutamol) and nonmedication-related resource use, including days in hospital, emergency room visits, specialist or primary care physician visits and other healthcare provider contacts. Indirect costs, including the number of days when the patient or their carer was unable to attend to their normal daily activities, were also assessed. The study assumed a European societal perspective (i.e. including direct and indirect costs).Results: Treatment with SMART resulted in significantly fewer severe exacerbations per patient per year compared with SFC (0.24 vs 0.31 events per patient per year; p = 0.0025). Resource use was low in both groups. Medication costs accounted for the majority of the total costs. The increased effectiveness of SMART was achieved at a reduced or similar cost compared with SFC. SMART dominated when German unit costs were applied (i.e. there was a statistically significant reduction in both costs and number of exacerbations). In all other countries, the incremental cost-effectiveness ratios showed that there was a reduction in mean total cost per exacerbation avoided; however, this difference was not statistically significant.Conclusion: This analysis demonstrates that, compared with SFC, SMART may be cost effective from a societal perspective for the treatment of patients with asthma in Italy, Germany, France and the UK. SMART provided a reduction in the number of severe exacerbations per patient per year, at no statistically significant increase in cost — or even at a lower cost — compared with SFC plus as-needed reliever salbutamol.

Cost-effectiveness analysis of budesonide/formoterol SMART therapy versus salmeterol/fluticasone plus as-needed SABA among patients ≥12 years with moderate asthma from the Chinese societal perspective

Budesonide/formoterol maintenance and reliever therapy in childhood asthma: Real-world effectiveness and economic assessment

Cost Effectiveness of Budesonide/Formoterol for Maintenance and Reliever Therapy versus Salmeterol/Fluticasone plus Salbutamol in the Treatment of Asthma

Cost-effectiveness Analysis on Salmeterol/Fluticasone Compound Vs.budesonide in the Treatment of Asthma

Budesonide/formoterol versus salmeterol/fluticasone for asthma in children: an effectiveness and safety analysis

Cost-effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland*

Budesonide/Formoterol Maintenance and Reliever Therapy in Chinese Patients with Asthma

Pharmcoeconomics of Budesonide/Formoterol versus Fluticasone/Salmeterol for Asthma:a Systematic Review

Treatment of Pediatric Mild Persistent Asthma with Low-Dose Budesonide Inhalation Suspension Vs.montelukast in China

Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov Model

Cost-Effectiveness Analysis of Formoterol Versus Salmeterol in Patients with Asthma

Cost-Effectiveness of Umeclidinium/Vilanterol versus Salmeterol/Fluticasone in Elderly Patients with Chronic Obstructive Pulmonary Diseases in China

Treatment of pediatric mild persistent asthma with low-dose budesonide inhalation suspension vs. montelukast in China

Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease.

A Three-Month Non-Interventional Study of Asthma Treatment with Budesonide/Formoterol

A Multicenter, Cross-Sectional, Observational Study of Budesonide/Formoterol Maintenance and Reliever Therapy in Real-World Settings

Cost-effectiveness of mepolizumab for severe eosinophilic asthma in China

[Evaluation of the Clinical Efficacy and the Safety of Salmeterol/fluticasone Propionate Accuhaler Compared to Budesonide Turbuhalar in the Control of Adult Asthma].

Budesonide/formoterol for maintenance and reliever therapy of asthma: a meta analysis of randomised controlled trials

Efficacy and Safety of Inhalation of Budesonide/Formoterol Via Turbuhaler® in Chinese Patients with Chronic Obstructive Pulmonary Diseas

[Pharmacoeconomics analysis of using a fixed combination of budesonide/formoterol in patients with asthma in the health care system of the Russian Federation]